UBS Ups AtriCure to Buy from Neutral

Analyst Patrick Pace thinks demand for the Management Information System procedure remains healthy

UBS Financial upgraded AtriCure (ATRC) to buy from neutral, after the company on Friday posted fourth quarter results.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.